DNAnexus and TMA Precision Health Join Forces to Improve Diagnostics and Treatment Options for Rare Diseases

Rare Daily Staff

Precision Health Data Cloud provider DNAnexus has entered into a collaboration with the rare disease health data platform TMA Precision Health to advance basic and translational research for patients who have a rare disease.

As part of the agreement, qualified researchers will be able to use the DNAnexus Precision Health Data Cloud and analysis tools to access and explore TMA’s whole genome sequencing data and associated longitudinal medical records. The companies said the collaboration will help scientists gain translational research insights that can improve diagnostic test selection and treatment options for patients with rare disorders.

Recent advances in whole genome sequencing allow researchers to capture large amounts of data required for discovering unknown etiological variants that cause many rare disorders. TMA’s platform deploys whole genome sequencing and disease reporting of patients across diverse geographies, connecting their consented and de-identified data to power research at scale and expand cohorts for clinical trials.

“TMA is focused on making clinical care more accessible and equitable for patients who have a rare disease,” said Thomas Laur, CEO at DNAnexus. “The combination of TMA’s whole genome sequencing datasets and medical data with our Precision Health Data Cloud will empower researchers to generate translational insights that can be used to treat patients today and advance the cures of tomorrow.”